Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Pharmaceutical Executive: September 2024
This month is as good a time as any to take a deep look at the transformations taking place in point-of-care delivery.
Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.
With a likely rate cut by the Federal Reserve this week, investors could rotate aggressively back to the sector.
The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.
As the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
As new litigation looms in the debate over use of copay accumulator programs, a look at potential next moves for payers—and steps drug manufacturers should take to ward off cost-driven non-adherence.
The industry holds the key to true change to the drug access landscape.
As HCPs continue to face time constraints and information overload, delivering relevant and personalized content becomes increasingly critical.
